Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Alessandra Blonda"'
Autor:
Steven Simoens, Khadidja Abdallah, Liese Barbier, Teresa Barcina Lacosta, Alessandra Blonda, Elif Car, Zilke Claessens, Thomas Desmet, Evelien De Sutter, Laurenz Govaerts, Rosanne Janssens, Teodora Lalova, Evelien Moorkens, Robbe Saesen, Elise Schoefs, Yannick Vandenplas, Eline Van Overbeeke, Ciska Verbaanderd, Isabelle Huys
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Countries are struggling to provide affordable access to medicines while supporting the market entry of innovative, expensive products. This Perspective aims to discuss challenges and avenues for balancing health care system objectives of
Externí odkaz:
https://doaj.org/article/bbc0089204d243a890fa9366197ff0a6
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction: The expansion of orphan drug treatment at increasing prices, together with uncertainties regarding their (cost-)effectiveness raises difficulties for decision-makers to assess these drugs for reimbursement. The present qualitative study
Externí odkaz:
https://doaj.org/article/6798b000a1b5411eafd595147812ea28
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2022)
Background: Nusinersen is an orphan drug intended for the treatment of spinal muscular atrophy (SMA), a severe genetic neuromuscular disorder. Considering the very high costs of orphan drugs and the expected market entry of cell and gene therapies, t
Externí odkaz:
https://doaj.org/article/e1e03758281e4d74afc3fcd47ef3e750
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Decision-makers have implemented a variety of value assessment frameworks (VAFs) for orphan drugs in European jurisdictions, which has contributed to variations in access for rare disease patients. This review provides an overview of the
Externí odkaz:
https://doaj.org/article/4b27a1756e7a4cd78839cff767e7640f
Publikováno v:
International Journal of Technology Assessment in Health Care. 38:S33-S34
IntroductionThe very high costs of orphan drugs, together with the uncertainties regarding their (cost-)effectiveness raise questions regarding the efficiency and legitimacy of their health technology assessment (HTA) and appraisal process. The aim o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6dbeaafb08ae594682642e6d7c2bf28
https://doi.org/10.1017/s0266462322001362
https://doi.org/10.1017/s0266462322001362
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2022)
Frontiers in Pharmacology, Vol 12 (2022)
Background: Nusinersen is an orphan drug intended for the treatment of spinal muscular atrophy (SMA), a severe genetic neuromuscular disorder. Considering the very high costs of orphan drugs and the expected market entry of cell and gene therapies, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ec28a8590b1a8b95d5382066a46b20
https://pubmed.ncbi.nlm.nih.gov/35126102
https://pubmed.ncbi.nlm.nih.gov/35126102
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Background: Decision-makers have implemented a variety of value assessment frameworks (VAFs) for orphan drugs in European jurisdictions, which has contributed to variations in access for rare disease patients. This review provides an overview of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d14d4567b10f2aeebc52b24d65ea158
https://doi.org/10.3389/fphar.2021.631527
https://doi.org/10.3389/fphar.2021.631527